Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma

Ovarian cancer patients with homologous recombination deficiency (HRD) tumors would benefit from PARP inhibitor (PARPi) therapy. However, patients with HRD tumors account for less than 50% of the whole cohort, so new biomarkers still need to be developed. Based on the data from the SNP array and som...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhiwen, Zhao, Qingguo, Lv, Bin, Qu, Xinyu, Han, Xiao, Wang, Hongyan, Qiu, Junjun, Hua, Keqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131501/
https://www.ncbi.nlm.nih.gov/pubmed/34047476
http://dx.doi.org/10.1002/ctm2.399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131501/
https://www.ncbi.nlm.nih.gov/pubmed/34047476
http://dx.doi.org/10.1002/ctm2.399

Ejemplares similares